Filing Details
- Accession Number:
- 0000899243-22-028481
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-08-12 16:15:57
- Reporting Period:
- 2022-08-10
- Accepted Time:
- 2022-08-12 16:15:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1805387 | Cerevel Therapeutics Holdings Inc. | CERE | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1830363 | John Renger | C/O Cerevel Therapeutics Holdings, Inc. 222 Jacobs Street, Suite 200 Cambridge MA 02141 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-08-10 | 29,624 | $3.50 | 32,328 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2022-08-10 | 25,376 | $10.28 | 57,704 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-08-10 | 36,141 | $40.19 | 21,563 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-08-10 | 18,859 | $41.10 | 2,704 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-08-10 | 29,624 | $0.00 | 29,624 | $3.50 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-08-10 | 25,376 | $0.00 | 25,376 | $10.28 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 80,146 | 2029-04-02 | No | 4 | M | Direct | |
| 134,915 | 2029-04-02 | No | 4 | M | Direct |
Footnotes
- These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.57 - $40.565. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.57 - $41.415. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
Billionaire Hedge Funds
